Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute...

Area of Science:

• Cardiology
• Clinical Medicine
• Pharmacology

Background:

• Acute myocardial infarction (AMI) management aims to improve patient outcomes.
• Left ventricular ejection fraction (LVEF) is a key prognostic indicator post-AMI.
• The role of beta-blocker therapy in AMI patients with varying LVEF requires further clarification.

Purpose of the Study:

• To investigate the association between beta-blocker therapy and clinical outcomes in acute myocardial infarction (AMI) patients.
• To specifically examine the impact of beta-blockers on patients with mid-range or preserved left ventricular systolic function.
• To determine if LVEF influences the effectiveness of beta-blocker treatment post-AMI.

Main Methods:

• Observational study using data from the Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH).
• Analysis of 12,200 in-hospital survivors of AMI.
• Comparison of 1-year major adverse cardiac events (MACE) between patients who received beta-blockers at discharge and those who did not, stratified by LVEF.

Main Results:

• Beta-blocker therapy was associated with significantly lower 1-year MACE (cardiac death, MI, revascularization, heart failure readmission) overall.
• This benefit was significant in patients with LVEF ≤40% and 40%
• No significant benefit of beta-blocker therapy was observed in patients with LVEF ≥50%.

Conclusions:

• Beta-blocker therapy at discharge is associated with improved 1-year clinical outcomes in AMI patients with reduced or mid-range LVEF.
• The benefit of long-term beta-blocker therapy post-AMI appears dependent on LVEF.
• LVEF should be considered when guiding the use of beta-blockers in AMI survivors.